🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Avistone Biotechnology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Avistone Biotechnology as lead sponsor. Synced 26 Sep 2026
10Current trials
7Recruiting now
7Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Avistone Biotechnology is the lead sponsor of 10 current clinical trials in our China and USA registers. 7 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are PLB1004, ANS014004 and Vebreltinib. The most-studied condition is Non-Small-Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting770%
  • Active, closed220%
  • By invitation110%

Trials by phase

  • Phase 1440%
  • Phase 2330%
  • Phase 1/2220%
  • Phase 3110%
01

Clinical trials sponsored by Avistone Biotechnology

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
NCT07336732 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
Drug: PLB1004
Phase 2 Recruiting 2026-03 China
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138 · Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Phase 1 Recruiting 2025-03 USA, China
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Drug: PLB1004
Phase 1 Recruiting 2024-07 USA
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
Drug: ANS014004
Phase 1 Recruiting 2024-06 USA, China
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
NCT06574347 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
Phase 2 Recruiting 2024-08 China
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
NCT07538804 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 1/2 Recruiting 2026-07 USA, China
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
NCT06343064 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
Phase 1/2 Recruiting 2023-06 China
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
NCT06281964 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
Phase 3 By invitation 2023-12 China
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
NCT06015503 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)
Drug: PLB1004
Phase 2 Active, closed 2023-07 China
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06328439 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
Drug: ANS014004
Phase 1 Active, closed 2024-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Avistone Biotechnology trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Avistone Biotechnology trials

5 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China96
Clinical trials in USA44

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Non-Small-Cell Lung Cancer

SponsorTrials
ArriVent BioPharma1
Astellas Pharma1

Sponsors with the most current trials registered for this condition.

06

Questions about Avistone Biotechnology trials

How many clinical trials does Avistone Biotechnology sponsor?

Avistone Biotechnology is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Avistone Biotechnology trials recruiting?

Yes. 7 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Avistone Biotechnology testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are PLB1004 (6), ANS014004 (2), Vebreltinib (2), Bozitinib (1) and Carboplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.